The company's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Pliant is also developing PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis in partnership with Novartis. Additionally, Pliant has two preclinical programs targeting oncology and muscular dystrophies. The company aims to build a patient registry to increase understanding of natural disease progression and fuel biomarker discovery.